However, it was found that approximately 20% of COVID‐19 convalescent patients, although producing antibodies to other SARS‐CoV‐2 antigens and epitopes, do not sufficiently produce RBD‐specific IgG antibodies to block the RBD‐ACE2 binding and hence are poor‐ or non‐responders to RBD.23, 24. The gene discussed is ACE2; the disease is COVID-19.